Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
0.770
-0.005 (-0.62%)
Nov 21, 2024, 11:14 AM EST - Market open
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 325 employees as of December 31, 2023. The number of employees decreased by 60 or -15.58% compared to the previous year.
Employees
325
Change (1Y)
-60
Growth (1Y)
-15.58%
Revenue / Employee
$456,745
Profits / Employee
-$269,166
Market Cap
96.52M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
23andMe Holding Co. | 582 |
FONAR | 520 |
Coherus BioSciences | 306 |
Adagene | 174 |
Immunic | 77 |
Assembly Biosciences | 65 |
Nuvectis Pharma | 13 |
Monopar Therapeutics | 10 |
KPTI News
- 19 hours ago - Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer - PRNewsWire
- 3 days ago - Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition - PRNewsWire
- 15 days ago - Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 - PRNewsWire
- 16 days ago - Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress - PRNewsWire
- 19 days ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 21 days ago - Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024 - PRNewsWire
- 21 days ago - Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis - PRNewsWire